Advice
Following an abbreviated submission
Alendronate/colecalciferol (Fosavance) is accepted for use within NHS Scotland for the treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency who require treatment with both alendronate and vitamin D and for whom once-weekly administration is appropriate. The combination preparation is cost saving compared to the two drugs administered separately.
Weekly administration of vitamin D represents a departure from routine clinical practice. In patients who also require calcium supplementation this will have to be administered separately, using a calcium preparation that does not also contain vitamin D.
Download detailed advice30KB (PDF)
Medicine details
- Medicine name:
- alendronate colecalciferol (Fosavance)
- SMC ID:
- 213/05
- Indication:
- Postmenopausal osteoporosis
- Pharmaceutical company
- MSD
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Superseded
- Date advice published
- 07 November 2005